Balaji Amines Limited, a leading manufacturer of Aliphatic Amines & Speciality Chemicals in India, specialised in manufacturing of Methyl Amines, Ethyl Amines, Derivatives of Amines and other Specialty Chemicals, announced its unaudited financial results for the quarter and half year ended September 30th, 2024.

Revenue from Operations for Q2FY25 stood at Rs. 356 crore, as compared to Rs. 393 crore in Q1FY25. PAT for Q2FY25 was Rs. 41 crore as compared to Rs. 46 crore in Q1 FY25. Diluted EPS for Q2 FY25 stood at Rs. 12.65 per equity share as against Rs. 13.36 in Q1 FY25. EBITDA for Q2 FY25 was Rs. 70 crore, as compared to Rs. 74 crore in Q1FY25. EBITDA margin for Q2FY24 stood at 20 per cent as against 19 per cent in Q1 FY25.

On the performance, D. Ram Reddy, Managing Director, commented, “In the Q2 quarter, we reported a revenue of Rs. 356 crore, achieving an EBITDA margin of 20%. This marks a 110-basis-point improvement over last quarter, reflecting our focus on higher margin products amid a challenging industry environment.

“While the broader market experienced pressure in Q2, both the API and agrochemical looks promising over a long term, and we are well-positioned to seize these future opportunities. With our expanded capacities and a sharpened focus on operational efficiency, we are confident in our ability to drive sustainable growth in the coming quarters.

“Our recent developments demonstrate significant progress in expanding our production capacity. With the successful commencement of Methylamines production at Unit-IV, our total annual installed capacity has increased from 48,000 MT to 88,000 MT across all three units. Additionally, Unit-I and Unit-III have achieved BIS Certification for 'Morpholine,' strengthening our quality standards and making us the only BIS-certified Morpholine manufacturer in India.

“Projects in Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether are also advancing well, reflecting our commitment to operational excellence. As we look forward, our strong foundation in core capabilities positions us well to navigate industry dynamics and capture growth opportunities. With a clear focus on our strengths, we are set to advance as a leader in Amines and Specialty Chemicals."